Shanghai RAAS(SZ:002252)2023-06-07 10:20Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is a leading enterprise in the blood products industry in China [2] - The company has four production entities and also acts as an agent for imported human albumin products, enhancing market competitiveness [4] Group 2: Plasma Collection and Product Trends - The annual plasma collection growth in the blood products industry is approximately 8%-10% [2] - The company aims to increase the utilization rate of raw plasma in coagulation factor products and expand its market share in this category [3] Group 3: Financial Performance and Profitability - The gross margin for the company's coagulation factor products is approximately 85% as reported in the 2022 annual report [4] - The gross margin for imported human albumin products is around 25%, with pricing largely consistent across different brands in the market [4] Group 4: Shareholding and Corporate Governance - The largest shareholder, Jilifu, holds 26.20% of the company's shares and has nominated five non-independent director candidates [3] - The company currently has no controlling shareholder or actual controller, which may change depending on the outcome of the upcoming shareholder meeting [3]